Insider Trading Alert - BLMT, COBZ And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 28, 2014, 67 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $849.00 to $372,250,000.00.

Highlighted Stocks Traded by Insiders:

BSB Bancorp (BLMT) - FREE Research Report

Downs Christopher Y, who is Executive Vice President at BSB Bancorp, bought 4,000 shares at $17.19 on April 28, 2014. Following this transaction, the Executive Vice President owned 58,422 shares meaning that the stake was reduced by 7.35% with the 4,000-share transaction.

The shares most recently traded at $17.34, up $0.15, or 0.87% since the insider transaction. Historical insider transactions for BSB Bancorp go as follows:

  • 4-Week # shares bought: 6,409
  • 12-Week # shares bought: 10,095
  • 24-Week # shares bought: 16,959

The average volume for BSB Bancorp has been 9,100 shares per day over the past 30 days. BSB Bancorp has a market cap of $155.0 million and is part of the financial sector and banking industry. Shares are up 13.39% year-to-date as of the close of trading on Monday.

BSB Bancorp, Inc. (Maryland) operates as the holding company for Belmont Savings Bank that provides financial services to individuals, families, and businesses. The company has a P/E ratio of 80.4.

Exclusive Offer: Get the latest Stock Analysis on BLMT - FREE

TheStreet Quant Ratings rates BSB Bancorp as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full BSB Bancorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CoBiz Financial (COBZ) - FREE Research Report

Vitale Mary Beth, who is Director at CoBiz Financial, bought 500 shares at $9.92 on April 28, 2014. Following this transaction, the Director owned 6,000 shares meaning that the stake was reduced by 9.09% with the 500-share transaction.

The shares most recently traded at $10.12, up $0.20, or 1.98% since the insider transaction. Historical insider transactions for CoBiz Financial go as follows:

  • 12-Week # shares bought: 789
  • 12-Week # shares sold: 16,767
  • 24-Week # shares bought: 789
  • 24-Week # shares sold: 16,767

The average volume for CoBiz Financial has been 93,100 shares per day over the past 30 days. CoBiz Financial has a market cap of $405.7 million and is part of the financial sector and banking industry. Shares are down 16.39% year-to-date as of the close of trading on Monday.

CoBiz Financial Inc., a diversified financial services company, provides various banking and financial products and services in the United States. The stock currently has a dividend yield of 1.19%. The company has a P/E ratio of 17.8. Currently, there are 3 analysts who rate CoBiz Financial a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on COBZ - FREE

TheStreet Quant Ratings rates CoBiz Financial as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full CoBiz Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al, who is CEO & Chairman at Opko Health, bought 36,200 shares at $8.04 on April 28, 2014. Following this transaction, the CEO & Chairman owned 140.6 million shares meaning that the stake was reduced by 0.03% with the 36,200-share transaction.

The shares most recently traded at $8.08, up $0.04, or 0.47% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 40,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 3.1 million shares per day over the past 30 days. Opko Health has a market cap of $3.4 billion and is part of the health care sector and health services industry. Shares are down 4.5% year-to-date as of the close of trading on Friday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently, there are 4 analysts who rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing